Pages that link to "Q35864072"
Jump to navigation
Jump to search
The following pages link to Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease (Q35864072):
Displaying 39 items.
- Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions (Q26863326) (← links)
- Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib (Q27853034) (← links)
- Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer. (Q31114848) (← links)
- Autophagy: A potential target for thyroid cancer therapy (Review) (Q33933013) (← links)
- Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models (Q34253418) (← links)
- Multikinase inhibitors use in differentiated thyroid carcinoma. (Q34660901) (← links)
- Molecular profiling of thyroid cancer subtypes using large-scale text mining (Q34914970) (← links)
- Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer (Q35876617) (← links)
- Serum microRNA profiling to distinguish papillary thyroid cancer from benign thyroid masses. (Q36030561) (← links)
- Patient Benefit-Risk Tradeoffs for Radioactive Iodine-Refractory Differentiated Thyroid Cancer Treatments (Q36366960) (← links)
- MicroRNA expression profiles in differentiated thyroid cancer, a review (Q36449793) (← links)
- Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer (Q36467394) (← links)
- Controversies in the management and followup of differentiated thyroid cancer: beyond the guidelines (Q36530119) (← links)
- A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment (Q36716739) (← links)
- Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer (Q36924717) (← links)
- Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment - initial experience. (Q37010592) (← links)
- Phosphatidylinositide 3-kinase (PI3K) and PI3K-related kinase (PIKK) activity contributes to radioresistance in thyroid carcinomas (Q37665265) (← links)
- Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma (Q38368008) (← links)
- Lenvatinib: A Review in Refractory Thyroid Cancer (Q38729953) (← links)
- Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer (Q44819667) (← links)
- 18F-FDG Pet-Guided External Beam Radiotherapy in Iodine-Refractory Differentiated Thyroid Cancer: A Pilot Study. (Q47114573) (← links)
- Papillary thyroid carcinoma expressing CD20. (Q50583371) (← links)
- Whole-remnant and maximum-voxel SPECT/CT dosimetry in 131 I-NaI treatments of differentiated thyroid cancer (Q50943856) (← links)
- Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials. (Q53109364) (← links)
- Prolonged duration of response in lenvatinib responders with thyroid cancer. (Q55413273) (← links)
- Impact of thyroiditis on 131I uptake during ablative therapy for differentiated thyroid cancer (Q64062811) (← links)
- Current controversies and future directions in the diagnosis and management of differentiated thyroid cancers (Q90042951) (← links)
- Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies (Q90163744) (← links)
- Selumetinib Activity in Thyroid Cancer Cells: Modulation of Sodium Iodide Symporter and Associated miRNAs (Q90293775) (← links)
- Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine (Q90387005) (← links)
- New Treatment Options for Metastatic Thyroid Cancer (Q91599204) (← links)
- Exposure-response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer (Q91656666) (← links)
- Risk of venous and arterial thromboembolic events associated with tyrosine kinase inhibitors in advanced thyroid cancer: a meta-analysis and systematic review (Q91756723) (← links)
- A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine (Q91924795) (← links)
- AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine Refractory Thyroid Cancer (Q92635483) (← links)
- POSTER PRESENTATIONS (Q94032441) (← links)
- Anaplastic thyroid cancer: How far can we go? (Q97420258) (← links)
- Immunotherapy for advanced thyroid cancers - rationale, current advances and future strategies (Q98665205) (← links)
- Combination therapy with lenvatinib and radiation significantly inhibits thyroid cancer growth by uptake of tyrosine kinase inhibitor (Q102331411) (← links)